---
layout: default
title: Amoxicillin Sodium
parent: 僅模型預測 (L5)
nav_order: 64
evidence_level: L5
indication_count: 0
---

# Amoxicillin Sodium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Amoxicillin Sodium: Antibiotic — Repurposing Evaluation Incomplete

## One-Sentence Summary

Amoxicillin Sodium is a widely used broad-spectrum β-lactam antibiotic registered in Malaysia under 5 product licenses.
The current Evidence Pack did not generate any TxGNN repurposing predictions due to missing critical data inputs — key data gaps including package insert warnings and mechanism of action must be resolved before a meaningful evaluation can proceed.
Until these gaps are addressed, no evidence level can be assigned and a **Hold** decision is recommended.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unavailable (license text not populated in Evidence Pack) |
| Predicted New Indication | None — no predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — below L5 (no predictions produced) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No predicted indications were generated in this Evidence Pack — the `predicted_indications` array is empty. This means the TxGNN pipeline did not produce any repurposing candidates for Amoxicillin Sodium under the current data configuration, and a standard mechanism-to-new-indication analysis cannot be performed.

Currently, detailed mechanism of action data is not available. Based on established pharmacological knowledge, Amoxicillin Sodium belongs to the aminopenicillin subgroup of β-lactam antibiotics, with its primary mechanism involving inhibition of bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). However, this information was not confirmed via DrugBank in the current Evidence Pack, and therefore cannot be formally relied upon for mechanism-of-action mapping within the TxGNN framework.

To unlock repurposing candidates, three inputs must first be in place: a confirmed DrugBank ID linked to Amoxicillin Sodium, populated approved indication text from NPRA license records, and resolved package insert data to pass the safety pre-screen. Once these are available, re-running the Knowledge Graph and Deep Learning prediction steps should produce meaningful candidates.

---

## Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack.

---

## Literature Evidence

Currently no related literature available in this Evidence Pack.

---

## Malaysia Market Information

Five product registrations were identified via NPRA query (query date: 2026-03-27) and the query was logged as successful (`result_count: 5`). However, all detailed license fields — license number, product name, dosage form, manufacturer, and approved indication text — were returned as empty strings, suggesting a data parsing or field-mapping issue downstream of the API call rather than a true absence of registrations.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|--------------|-------------|---------------------|
| (Not populated) | (Not populated) | (Not populated) | (Not populated) |
| (Not populated) | (Not populated) | (Not populated) | (Not populated) |
| (Not populated) | (Not populated) | (Not populated) | (Not populated) |
| (Not populated) | (Not populated) | (Not populated) | (Not populated) |
| (Not populated) | (Not populated) | (Not populated) | (Not populated) |

> **Action required:** The NPRA returned 5 records but field mapping failed. Re-run the data parsing pipeline against the raw NPRA response to repopulate these rows before downstream analysis.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Both key warnings and contraindications carry outstanding data gaps at **Blocking** severity (DG001), which prevents safety pre-screening from proceeding. No drug-drug interaction records were identified (DDI query returned 0 results). Safety evaluation is fully blocked until package insert data is retrieved from the NPRA official source and parsed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN repurposing predictions were generated and two critical data gaps — a Blocking-severity gap on package insert warnings and a High-severity gap on mechanism of action — prevent both safety pre-screening and mechanism-of-action analysis. This evaluation cannot advance until the gaps below are resolved.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Download and parse the package insert PDF from the NPRA official website to extract warnings, precautions, and contraindications for Amoxicillin Sodium
- **[DG002 — High]** Query the DrugBank API to confirm the DrugBank ID and retrieve full MOA data; a confirmed ID is a prerequisite for KG-based prediction
- **[License data repopulation]** Investigate why the 5 NPRA-registered product records returned with all empty fields; inspect the raw API response and fix the field-mapping logic in the data processing pipeline
- **[Re-run TxGNN pipeline]** Once DrugBank ID is confirmed and indication text is available, re-execute `run_kg_prediction.py` and `txgnn_model.py` to generate repurposing candidates
- **[Evidence collection]** After predictions are generated, run ClinicalTrials.gov and PubMed collectors against the top-ranked predicted indication to build an evidence table and assign a formal evidence level (L1–L5)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

